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Abstract 24 
Endometrial cancer (EC) is the most common gynaecological malignancy. Obesity is a major 25 
risk factor for EC and is associated with elevated cholesterol. 27-Hydroxycholesterol (27HC) 26 
is a cholesterol metabolite that functions as an endogenous agonist for Liver X Receptor 27 
(LXR) and a selective estrogen receptor modulator (SERM). Exposure to estrogenic ligands 28 
increases risk of developing EC however the impact of 27HC on EC is unknown. 29 
Samples of stage 1 EC (n=126) were collected from post-menopausal women undergoing 30 
hysterectomy. Expression of LXRs (NR1H3, LXRα; NR1H2, LXRβ) and enzymes required 31 
for the synthesis (CYP27A1) or breakdown (CYP7B1) of 27HC were detected in all grades of 32 
EC. Cell lines originating from well-, moderate- and poorly-differentiated endometrial cancers 33 
(Ishikawa, RL95, MFE 280 respectively) were used to assess the impact of 27HC or the LXR 34 
agonist GW3965 on proliferation or expression of a luciferase reporter gene under the 35 
control of LXR- or ER-dependent promoters (LXRE, ERE). Incubation with 27HC or GW3965 36 
increased transcription via LXRE in Ishikawa, RL95 and MFE 280 cells (p<0.01). 27HC 37 
selectively activated ER-dependent transcription (p<0.001) in Ishikawa cells and promoted 38 
proliferation of both Ishikawa and RL95 cells (p<0.001). In MFE 280 cells 27HC did not alter 39 
proliferation but selective targeting of LXR with GW3965 significantly reduced cell 40 
proliferation (p<0.0001).  41 
These novel results suggest that 27HC can contribute to risk of EC by promoting 42 
proliferation of endometrial cancer epithelial cells and highlight LXR as a potential 43 
therapeutic target in the treatment of advanced disease.   44 
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Introduction 45 
Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth 46 
most common cancer in women in developed countries with incidence increasing in line with 47 
rising rates of obesity (reviewed in (Onstad, et al. 2016)). Obesity is a major modifiable risk 48 
factor for EC and is thought to contribute to increased risk of malignancy in part due to 49 
increased exposure to estrogens which enhance risk of aberrant proliferation within the 50 
endometrium (Sanderson, et al. 2017). Obesity is also is associated with an adverse 51 
metabolic profile which is postulated to independently increase risk of EC (Trabert, et al. 52 
2015). 53 
A recent meta-analysis supported a positive association between dietary cholesterol 54 
consumption and endometrial cancer risk (Gong, et al. 2016). Notably, obesity also puts 55 
individuals at risk of developing an adverse, raised, cholesterol profile. Cholesterol 56 
metabolites such as the oxysterol 27-hydroxycholesterol (27HC) have been demonstrated to 57 
promote cancer growth and metastasis in studies on breast cancer (Nelson, et al. 2013; Wu, 58 
et al. 2013a); providing a plausible mechanistic link between increased adiposity and EC 59 
risk. 27HC is a primary metabolite of cholesterol, synthesised by the action of sterol 27-60 
hydroxylase (CYP27A1) and metabolised by 25-hydroxycholesterol 7-α-hydroxylase 61 
(CYP7B1; [1]). 27HC acts as an endogenous agonist for the Liver X receptor (LXR), a ligand 62 
activated transcription factor involved in the regulation of cholesterol homeostasis. Two 63 
isoforms of LXR have been identified; LXRα (encoded by NR1H3) which is predominantly 64 
expressed in the liver, kidney and small intestine but exhibits low expression in other tissues, 65 
and LXRβ (encoded by NR1H2) which is ubiquitously expressed. Based largely on studies in 66 
breast cancer, LXRs have been proposed as a novel anti-cancer target and the LXR-67 
selective agonists GW3965 and T0901317 are reported to decrease proliferation of LXR-68 
expressing breast cancer cell lines (MCF7, T47D, MDA-MB231) as well as the prostate 69 
cancer cell line LNCaP (Kim, et al. 2010; Vedin, et al. 2009). To the best of our knowledge 70 
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LXR expression has not been reported in human EC tissues and the impact of either 27HC 71 
or LXR agonists on the endometrium or endometrial malignancies is not known.  72 
 In addition to activating LXRs, 27HC can also bind estrogen receptors (ER) 73 
(Umetani, et al. 2007) and acts as an endogenous selective estrogen receptor modulator 74 
(SERM) (DuSell, et al. 2008). 27HC has diverse impacts and its SERM activity is reported to 75 
be both tissue-selective and context-dependent. For example, 27HC acts as a competitive 76 
antagonist of ERs expressed in the vasculature and can antagonise E2-mediated endothelial 77 
cell migration and re-endothelialisation (Umetani et al. 2007). In contrast, in the absence of 78 
E2, 27HC is reported to act as an agonist to ERα (ESR1) to increase cell adhesion and 79 
expression of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNFA) and 80 
interleukin 6 (IL6) (Umetani, et al. 2014) by endothelial cells and macrophages. Notably, 81 
27HC is also reported to increase proliferation of ERα-positive breast cancer cell lines and 82 
promotes MCF7 tumour xenograft growth in mice by stimulating ER-dependent cell 83 
proliferation (Wu et al. 2013a). Given selective LXR agonists have anti-proliferative effects 84 
(Vedin et al. 2009), these studies suggest that proliferative effects of 27HC may be mediated 85 
via ER and that relative expression of LXR or ER isoforms may define the impact of the 86 
ligand.  87 
ER isoforms are expressed in EC tissues and ER expression changes with disease 88 
progression (Collins, et al. 2009). We have previously reported that ERα is readily detectable 89 
in both epithelial and stromal cells in well-differentiated cancers but is significantly reduced in 90 
poorly-differentiated cancers. In contrast, expression of ESR2 variants (ERβ1, 2, 5) was 91 
readily detected in well, moderate and poorly differentiated stage 1 ECs (Collins et al. 2009). 92 
We therefore postulated that 27HC might have distinct effects in EC depending on the 93 
bioavailability of ER isoforms present at different stages of disease progression.  94 
 Obesity and the metabolic syndrome are both associated with an increased risk of 95 
developing pre-malignant and malignant endometrial disease (Sanderson et al. 2017) but 96 
whether the cholesterol metabolite 27HC has an impact on endometrial cancer 97 
risk/progression is not known. In the current study we assessed the expression of the 98 
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enzymes required for synthesis (CYP27A1) and breakdown (CYP7B1) of 27HC and 99 
assessed expression of the cognate receptors LXRα and LXRβ in primary human stage I 100 
endometrial adenocarcinomas (n=126) and postmenopausal endometrial controls (n=9). The 101 
impact of 27HC and the LXR-selective agonist GW3965 on ERE- and LXRE-dependent 102 
expression of a reporter gene, as well as cellular proliferation, was assessed in three 103 
endometrial cancer cell lines which phenocopy well-, moderately- and poorly-differentiated 104 
stage I endometrial cancers. Our novel findings demonstrate that 27HC can alter responses 105 
in endometrial cancer cells and highlight LXR as a potential therapeutic target. Taken 106 
together our findings suggest increased exposure to 27HC may increase risk of development 107 
and progression of endometrial cancer.   108 
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Materials and methods 109 
Human tissue samples  110 
Endometrial adenocarcinoma tissue was collected from post-menopausal women 111 
undergoing total abdominal hysterectomy who had been previously diagnosed to have 112 
endometrioid adenocarcinoma of the endometrium; they had received no treatment before 113 
surgery (supplementary table 1). Written informed consent was obtained from all subjects 114 
prior to surgery, and ethical approval was granted by the Lothian Research Ethics 115 
Committee (LREC1999/6/4). Methods were carried out in accordance with NHS Lothian 116 
Tissue Governance guidelines.  All endometrial cancers were confined to the uterus 117 
(International Federation of Obstetrics and Gynaecology, FIGO, stage 1 as described in 118 
(Collins et al. 2009)). Diagnosis of adenocarcinoma was confirmed histologically by an 119 
experienced gynaecological pathologist and tissues were further graded as well 120 
differentiated (G1), moderately differentiated (G2) or poorly differentiated (G3). Samples 121 
were anonymised and patient follow-up information was not available. However, survival 122 
statistics for stage 1 EC in the UK are reported as 99% 1-year survival and 95.3% 5-year 123 
survival (Cancer Research UK; http://www.cancerresearchuk.org/health-professional/cancer-124 
statistics/statistics-by-cancer-type/uterine-cancer/ accessed November 2017) and 125 
Information Services Division Scotland figures, which cover the stage 1 EC samples 126 
collected in the current study, report 92.9% 1-year survival and 83.2% 5-year survival for all 127 
uterine cancers (http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Female-128 
Genital-Organ/#uterus accessed November 2017). 129 
Postmenopausal controls (n=9) were obtained from women undergoing surgery for non-130 
malignant gynaecological conditions. None of the women were receiving hormonal therapy.  131 
A total of 126 EC tissue samples were analysed; 3 samples per grade were assessed for 132 
immunohistochemistry and n=30 well differentiated cancers, n=64 moderately differentiated 133 
and n=32 poorly differentiated samples were assessed for qPCR studies. A minimum of 10 134 
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samples at each grade were analysed for each gene, detailed sample numbers are included 135 
in supplementary table 2. Tissue for immunohistochemistry was collected in neutral buffered 136 
formalin (NBF), RNA extraction samples were collected in RNALater (Qiagen, UK). 137 
Measurement of mRNA  138 
Isolation of mRNAs, preparation of cDNAs, and analysis by qPCR was performed according 139 
to standard protocols (Bombail, et al. 2010); samples were quantified by relative standard 140 
curve method or by the comparative ∆∆Ct method with CYC as internal control. 141 
Primers/probes are given in supplementary table 3.  142 
Immunohistochemistry 143 
Single antibody immunohistochemistry using 3,3'-diaminobenzidine tetra-hydrochloride 144 
(DAB) detection was performed as described previously (Collins et al. 2009). Double 145 
immunofluorescence was carried out with antibodies directed against LXR or ERα and the 146 
proliferation marker Ki67. Details of antibodies and dilutions are provided in supplementary 147 
table 4. Primary antibodies were incubated at 4°C overnight. Antigen detection was 148 
performed using Tyramide signal amplification (Perkin Elmer) system followed by nuclear 149 
counterstaining with DAPI (4’, 6-Diamidino-2-phenyl-indole dihydrochloride). Negative 150 
controls were incubated in the absence of primary antibody but otherwise processed as 151 
above; no staining was detected in no primary controls for any of the antibodies used (not 152 
shown). Images were captured using a LSM 710 Confocal microscope (Zeiss) at x40 153 
magnification.  154 
Cell Cultures 155 
Three endometrial adenocarcinoma cell lines representative of well-, moderately- or poorly-156 
differentiated cancers were used. Ishikawa cells were obtained from the European Collection 157 
of Cell Culture (ECACC no 99040201, Wiltshire, UK). This cell line was originally derived 158 
from a well-differentiated adenocarcinoma of a 39 year-old woman (Nishida, et al. 1985) and 159 
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reported to express both ERα and ERβ protein (Johnson, et al. 2007). RL95-2 cells (ATCC® 160 
CRL-1671™; hereafter RL95) were originally derived from a Grade 2 moderately 161 
differentiated endometrial adenocarcinoma (Way, et al. 1983) and reported to express both 162 
ERα and ERβ protein (Li, et al. 2014; Yang, et al. 2008). MFE-280 (ECACC no 98050131) 163 
were derived from a recurrent, poorly differentiated, endometrial adenocarcinoma and have 164 
low/undetectable expression of ERα and ERβ. Cells were maintained in DMEM/F12 (Sigma) 165 
supplemented with 10% FBS, 100U penicillin, streptomycin and 0.25 µg/ml fungizone 166 
(Invitrogen, Paisley, UK) at 37°C in 5% CO2. Media for RL95 was supplemented with 167 
0.005mg/ml Insulin (Sigma). Cells were incubated with 27-hydroxycholesterol (27HC; Tocris 168 
Cat. No. 3907) using stocks diluted in ethanol to give final concentrations ranging from 10-5M 169 
to 10-8M or GW 3965 hydrochloride (GW; Tocris Cat. No. 2474) using stocks diluted in 170 
DMSO to give final concentrations ranging from 10-5M to 10-8M. Some cultures were co-171 
incubated with the anti-estrogen fulvestrant (ICI 182,780; Tocris Cat. No. 1047) diluted in 172 
DMSO at a final concentration of 10-6M. Appropriate vehicle control incubations were 173 
included in all studies. All cell lines were authenticated using the Promega PowerPlex 21 174 
system (Eurofins Genomics, Ebersberg, Germany). 175 
Reporter assays 176 
An adenoviral vector containing a 3xERE-tk-luciferase reporter gene was prepared as 177 
described previously (Collins et al. 2009). Cells were cultured in DMEM without phenol red 178 
and containing charcoal stripped foetal calf serum (CSFCS) for 24 hours before being 179 
infected with Ad-ERE-Luc at a MOI of 25. Activation of LXR-dependent signal transduction 180 
was assessed according to manufacturer’s instructions using reagents from the Cignal LXR 181 
Reporter Kit which includes positive and negative controls as well as a luciferase reporter 182 
gene under the control of tandem repeats of the LXR transcriptional response element 183 
(LXRE) (Qiagen, CCS-0041L).  184 
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Cells were treated for 24 hours and luciferase activities were determined using 'Bright Glo' 185 
reagents (Promega). Luminescence was measured using Fluostar Microplate Reader (BMG 186 
labtech) and fold change in luciferase activity calculated relative to vehicle control for each 187 
treatment. 188 
Proliferation assays 189 
The impact of treatments on cell proliferation was assessed using CyQUANT® Direct Cell 190 
Proliferation Assay (Thermo Fisher, C35011) according to manufacturer’s instructions and 191 
nuclear fluorescence measured using Novostar Microplate Reader (BMG labtech). For each 192 
cell line investigated, cell number was quantified using a standard curve of known cell 193 
numbers and fold change in cell number calculated relative to vehicle control for each 194 
treatment. 195 
Statistical analysis 196 
Statistical analysis was performed using Graphpad prism. One-way ANOVA was used to 197 
determine significance between treatments in data that were normally distributed. Non-198 
parametric testing was utilised where sample sizes were insufficient to confirm normality of 199 
data distribution; Kruskal-Wallis test was used to assess differences between treatments. 200 
Where data were analysed as fold-change significance was tested using one sample t test 201 
and a theoretical mean of 1. Criterion for significance was p<0.05. All data are presented as 202 
mean ± SEM. 203 
Results 204 
Enzymes that regulate bioavailability of 27-hydroxycholesterol and its cognate receptor LXR 205 
are expressed in endometrial cancer. 206 
Messenger RNAs encoded by CYP7B1 and CYP27A1 were detected in all cancer grades 207 
(Figure 1A and B); expression of CYP7B1 was significantly lower in poorly-differentiated 208 
cancers compared to moderately differentiated cancers (p<0.05). Relative expression of 209 
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CYP27A1 tended to be higher in poorly differentiated cancers but this was not significant. 210 
We next assessed relative expression of mRNAs encoding the LXR receptors known to bind 211 
27HC: NR1H3 (LXRα) and NR1H2 (LXRβ) were detected in all cancer grades (Figure 1C 212 
and D). Expression of NR1H3 was significantly lower in moderately-differentiated cancers 213 
compared to post-menopausal controls (p<0.01). Expression of NR1H2 did not change 214 
between sample groups.  215 
Immunolocalisation of LXR and the proliferation marker Ki67 in endometrial cancer tissue 216 
sections. 217 
The expression of LXR in endometrial cancer tissue sections was assessed by 218 
immunohistochemistry using an antibody that detected both isoforms of LXR (mouse anti-219 
LXR; sc-271064). LXR was readily detected in well-, moderately- or poorly-differentiated 220 
cancers and was immunolocalised to both stromal and epithelial cells (supplementary figure 221 
1). To assess if LXR expression was associated with cell proliferation within endometrial 222 
cancer tissue we performed double immunofluorescence staining for both LXR and the 223 
proliferation marker Ki67 (Figure 2). In well-differentiated cancers (Figure 2A), nuclear 224 
immunoexpression of Ki67 (red staining) was detected which co-localised (yellow arrows) 225 
with LXR expression (green staining, note that single channel views show that the intensity 226 
of LXR staining varied between cells). Whilst careful evaluation of single channel views 227 
confirmed that the majority of LXR-positive cells were also immunopositive for Ki67 some 228 
cells were Ki67-negative (white arrows). In contrast, in moderately-differentiated cancers 229 
(Figure 2B) both markers were detected but few cells appeared to co-localise (yellow 230 
arrows) although LXR-positive cells (white arrows) were found in close association with 231 
proliferating cells. In poorly differentiated cancers (Figure 2C), few cells expressed both 232 
markers. Ki67-positive cells were clustered in regions with limited LXR expression and no 233 
co-expression of LXR and Ki67 was detected. LXR+Ki67- cells (white arrows) were detected 234 
close to Ki67+ cells. We also assessed the expression of ERα and Ki67 in endometrial 235 
cancer tissues (supplementary figure 2) as this receptor is implicated in regulation of 236 
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proliferation in normal endometrium (Frasor, et al. 2003; Lubahn, et al. 1993). Consistent 237 
with our previous study, ERα was not detected in the poorly differentiated cancers (Collins et 238 
al. 2009) and immunoexpression of Ki67 was clearly independent of ERα with an increase in 239 
abundance of positive nuclei in poor (sample codes 910/2178) as compared to well or 240 
moderately differentiated tissue where co-localisation of ERα and Ki67 was readily detected. 241 
27HC activates LXRE- and ERE-dependent transcription in endometrial epithelial cancer 242 
cells and alters proliferation of endometrial cancer cells 243 
Having demonstrated expression of enzymes and receptors required for 27HC signalling, we 244 
extended our observational study by exploring the impact of the ligand on endometrial 245 
epithelial cancer cell lines chosen to model well-, moderately- or poorly-differentiated stage I 246 
cancers; Ishikawa, RL95 and MFE 280. Protein expression of both LXR isoforms was 247 
confirmed by western blot in all cell lines studied (supplementary figure 3A and 3B). We 248 
assessed the mRNA expression of LXRs in these cell lines and found that their expression 249 
phenocopied that found in tissue samples (Supplementary figure 3). NR1H3 mRNA 250 
expression was significantly decreased in RL95 (moderately-differentiated) cells compared 251 
to MFE 280 (poorly-differentiated; p<0.01; Supplementary figure 3C). Consistent with tissue 252 
mRNA expression patterns NR1H2 was not different between cell lines (Supplementary 253 
figure 3D). Messenger RNAs encoded by both ER genes; ERα (ESR1) and ERβ (ESR2; 254 
ERβ1 specific primers) were detected in all of the cell lines (Supplementary figure 4). ESR1 255 
mRNAs were significantly reduced in RL95 and MFE280 compared to Ishikawa cells 256 
(Supplementary figure 4A) consistent with patterns of expression in intact tissue 257 
(supplementary figure 2). ESR2 mRNA was significantly reduced in MFE280 cells compared 258 
to Ishikawa (Supplementary figure 4B). As 27HC is both an endogenous agonist for LXR and 259 
a SERM, the impact of 27HC on LXRE- and ERE-dependent transcription was investigated 260 
in the endometrial cancer cell lines. 27HC significantly increased LXRE-dependent 261 
transcription in a dose-dependent manner in all 3 cell lines and was maximally stimulated by 262 
10-5M 27HC (Figure 3 A-C). In contrast, 27HC only stimulated ERE-dependent transcription 263 
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in Ishikawa cells (Figure 3D) at 10-8M (p<0.01) and 10-7M (p<0.0001). The impact of 27HC 264 
was abrogated by co-incubation with the anti-estrogen Fulvestrant (ICI 182,780) consistent 265 
with ER dependence. In contrast to Ishikawa cells, 27HC had little impact on ERE-266 
dependent transcription in RL95 (Figure 3E) and MFE280 cells (Figure 3F). As 27HC could 267 
activate both ERE- and LXRE-promoters, we assessed its impact on cell proliferation (Figure 268 
3 G-I). 27HC induced proliferation of Ishikawa cells at concentrations ranging from 10-8M to 269 
10-6M (p<0.01) but this was inhibited at the highest concentration (10-5M, p<0.0001). 27HC 270 
significantly increased proliferation in RL95 cells at concentrations of 10-7M (p<0.001) or 271 
greater. In contrast, 27HC did not alter proliferation of MFE 280 cells at any of the 272 
concentrations investigated. Neither RL95 nor MFE280 cell lines expressed CYP7B1 273 
(supplementary figure 3E and 3F) precluding the potential for in vitro metabolism limiting cell 274 
responses to 27HC in these cell lines. 275 
Targeting LXR with the synthetic agonist GW3965 activates LXRE-dependent transcription 276 
and alters cell proliferation in a cell specific manner. 277 
Incubation of cells with the LXR-selective agonist GW3965 significantly increased LXRE-278 
dependent transcription in a dose-dependent manner (Figure 4) consistent with expression 279 
of LXRs in the endometrial cancer cell lines (Supplementary Figure 3). In contrast to 27HC, 280 
GW3965 significantly and robustly increased LXRE-dependent transcription at 281 
concentrations ≥10-8M in Ishikawa (Figure 4A) and RL95 (Figure 4B) and ≥10-7M in MFE280 282 
cells (Figure 4C). Although LXR reporter responses were similar in the different cell lines, 283 
proliferation responses were strikingly different. In Ishikawa cells, treatment with GW3965 at 284 
concentrations 10-8M (p<0.01) and 10-5M (p<0.01) significantly increased proliferation 285 
(Figure 4D). In contrast, GW3965 significantly and robustly decreased cell proliferation at all 286 
concentrations investigated in both RL95 (Figure 4E) and MFE 280 cells (Figure 4F). 287 
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Discussion 288 
To date, no study has assessed the association between the cholesterol metabolite 27HC 289 
and EC. EC incidence rates have increased by ~50% since the early 1990s and 290 
approximately 57% of endometrial cancers in the United States have been attributed to 291 
being overweight or obese (Cancer Research UK; http://www.cancerresearchuk.org - 292 
accessed November 2017, and (Calle and Kaaks 2004)). Although increased exposure to 293 
adipose-derived estrogens is believed to increase aberrant proliferation within the 294 
endometrium (Zhao, et al. 2016), recent evidence supports an independent role for obesity-295 
associated metabolic factors in modulating EC risk. Notably, both elevated triglycerides and 296 
increased dietary cholesterol consumption are reported to be associated with increased EC 297 
risk (Gong et al. 2016; Lindemann, et al. 2009). Importantly, concentrations of the 298 
cholesterol metabolite 27HC are increased in postmenopausal women (Burkard, et al. 2007) 299 
and are associated with increased risk of breast cancer. Several studies have identified that 300 
27HC has an adverse impact on breast cancer (Nelson et al. 2013; Wu et al. 2013a) but 301 
whether 27HC can affect EC has not previously been investigated.  302 
In light of these studies we hypothesised that 27HC signalling could contribute to the 303 
aetiology of endometrial cancer and influence disease progression and we investigated this 304 
using both archival human tissue as well as cell lines that are derived from different grades 305 
of EC. We obtained new evidence for expression of the enzymes required for the both the 306 
synthesis (CYP27A1) and breakdown (CYP7B1) of 27HC. As concentrations of CYP7B1 307 
mRNAs were significantly decreased in poorly- compared to moderately-differentiated 308 
cancers and expression of CYP27A1 did not change significantly across EC grades; we 309 
believe this would favour increased bioavailability of 27HC with increasing grade. These 310 
findings appear to parallel those reported for ER+ breast cancer where decreased 311 
expression of CYP7B1 and increased CYP27A1 has been reported in tumours compared to 312 
normal breast tissues (Wu et al. 2013a). Furthermore, we found that the endogenous 313 
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receptor for 27HC, LXR, was immunolocalised to stage 1 cancers and was expressed 314 
throughout the tissue and localised to the nuclei of both stromal and epithelial cells.  315 
We sought to establish if 27HC could alter responses in endometrial cancer cells by acting 316 
via its cognate receptor, LXR, or via estrogen receptors which are known to regulate 317 
endometrial proliferation. 27HC activated LXR-dependent transcription in all cell lines tested. 318 
In contrast, we found that 27HC activated ERE-dependent reporter gene expression in well-319 
differentiated cancer cells (Ishikawa; ERα+ERβ+) but not in those from moderately- (RL95; 320 
ERαlowERβ+) or poorly-differentiated cancers (MFE280; ERαlowERβlow). However, 27HC 321 
increased proliferation of both Ishikawa and RL95 cells but not MFE280 cells consistent with 322 
reported ER expression in these cell lines (Johnson et al. 2007; Li et al. 2014; Yang et al. 323 
2008). Our immunohistochemistry analysis (supplementary figure 2) supported these in vitro 324 
findings. We found that the proliferation marker Ki67 co-localised with ERα in well- and 325 
moderately-differentiated cancers consistent with a key role for this receptor in mediating 326 
endometrial epithelial cell proliferation (Frasor et al. 2003; Lubahn et al. 1993). In poorly-327 
differentiated cancers, ERα was not detected consistent with previous reports (Collins et al. 328 
2009). It has been reported that 27HC, acting as a SERM, can impact on ERα- or ERβ1-329 
dependent regulation of cell function (He and Nelson 2017) and the estrogenic effects of 330 
27HC could therefore be mediated via either ER isoform in EC cells. In endometrial 331 
endothelial cells, which express ERβ but not ERα, estrogenic effects are mediated via ERβ 332 
tethered to Sp1 and not via direct binding to ERE (Greaves, et al. 2013). Furthermore, it has 333 
been reported that 27HC promotes proliferation of ERα-positive LNCaP prostate cancer cells 334 
via ERβ (Lau, et al. 2000) (Raza, et al. 2017) which may account for the apparent 335 
discrepancy between ERE reporter assay and cell proliferation responses in RL95 cells 336 
observed in the current study. Taken together, these findings reveal the potential for 27HC 337 
generated within the EC tissue microenvironment to influence ER-dependent transcription 338 
and proliferation via ERs expressed in early grade stage 1 EC.  339 
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Although the association between ERs and endometrial proliferation is well recognised, 340 
there is limited data investigating the role of LXR in this process. Expression of LXRα and 341 
LXRβ mRNA has been previously reported in endometrium and myometrium of mice 342 
(Mouzat, et al. 2007) and 27HC is reported to increase mouse uterine weight, consistent with 343 
an uterotrophic action, however, whether this was mediated via ER or LXR was not 344 
investigated (Wu, et al. 2013b). In mice, targeted ablation of the receptor subtypes revealed 345 
that Lxrα-/- but not Lxrβ-/- females had reduced endometrial areas compared to wildtype 346 
mice consistent with a role for LXRα in promoting endometrial growth/proliferation in that 347 
species (Mouzat et al. 2007). In the current study we found that LXR co-localised with the 348 
proliferation marker Ki67 in well-differentiated but not moderate- or poorly differentiated EC 349 
tissues. In vitro assays verified this finding as the synthetic LXR agonist GW3965 had a cell-350 
selective impact on the EC cell lines. In Ishikawa cells GW3965 increased proliferation, 351 
whereas in RL95 and MFE280 cells equimolar concentrations of agonist blocked 352 
proliferation. Given that LXR expression was detected in all grades of endometrial cancer 353 
this may suggest LXR could be an effective therapeutic target in some endometrial cancers, 354 
albeit in a grade-dependent context. Indeed, GW3965, is reported to abrogate E2-mediated 355 
increases in MCF7 breast cancer cell proliferation and has been proposed as an anti-356 
proliferative ligand in this context (Vedin et al. 2009).  357 
LXR classically acts as a heterodimeric partner of retinoid X receptor (RXR). RXR is 358 
expressed in the nuclei of endometrial epithelial cells throughout the menstrual cycle 359 
(Fukunaka, et al. 2001) as well as in endometrial cancer tissues (Nickkho-Amiry, et al. 360 
2012). Interestingly, LXR-RXR functions as a ‘permissive’ heterodimer and binding of either 361 
an LXR agonist or the RXR agonist 9-cis retinoic acid activates transcription, while agonism 362 
of both dimer partners has an additive effect on activation. Assessment of RXR isoforms in 363 
the cell lines used in the current study demonstrated differential expression of RXRs in 364 
Ishikawa, RL95 and MFE280 cells which may account for the distinct responses of these cell 365 
lines in response to GW3965 treatment (supplementary figure 5). NR2B1 (RXRα) mRNA 366 
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expression was greatest in RL95 cells while NR2B2 (RXRβ) was detected in all cell lines. 367 
Notably, mRNA expression of NR2B3 (RXRγ) was not detected in RL95 cells but was 368 
abundant in MFE280 cells. Whether changes in the constitution of the receptor isoforms that 369 
contribute to the LXR:RXR heterodimer affect responses requires further investigation, 370 
however, previous studies demonstrate that targeting retinoid signalling may affect 371 
proliferation of EC cells. Notably, retinoic acid (RA) signalling via retinoic acid receptor 372 
(RAR) and RXR is reported to inhibit Ishikawa cell proliferation by inducing cell cycle arrest 373 
(Cheng, et al. 2011) and fenretinide, a synthetic derivative of RA, induced apoptosis of 374 
Ishikawa cells (Mittal, et al. 2014). These results suggest targeting LXR-dependent signalling 375 
with LXR and/or RXR agonists could inhibit proliferation in EC and cancer progression.  376 
Changes in the local inflammatory environment that occur during development and 377 
progression of endometrial cancer may also increase exposure to 27HC due to infiltration of 378 
inflammatory cells. We have previously demonstrated that infiltration of immune cells is 379 
increased in endometrial cancer tissues compared to controls. Notably, the numbers of 380 
macrophages, neutrophils and dendritic cells were significantly increased in EC tissues 381 
(Wallace, et al. 2010) consistent with 27HC-dependent increases in migration of bone 382 
marrow-derived CD11b+ cells reported in in vitro assays (Raccosta, et al. 2013). In addition, 383 
27HC increases secretion of CCL2 from macrophages which enhances recruitment of 384 
monocytes (Kim, et al. 2013) and can also upregulate ER-dependent expression of pro-385 
inflammatory genes (Umetani et al. 2014). Notably, as Cyp27a1 is reported to be abundant 386 
in macrophages [2], these cells may also contribute to an increase in 27HC within the 387 
tumour microenvironment. In support of this idea, increased 27HC concentrations have been 388 
reported in breast cancer tumours (Wu et al. 2013b) and increased concentrations of 389 
cholesterol have been reported in tumours of various cancer types although they have not 390 
been directly measured in EC. 27HC can also promote secretion of TNFA and IL6 from 391 
macrophages and TNFA is reported to increase proliferation of human endometrial glandular 392 
epithelial cells (Nair, et al. 2013). Thus, although in the current study we only investigated 393 
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the direct impact of 27HC on proliferation of endometrial cancer epithelial cells, 27HC may 394 
also exacerbate changes within the tissue microenvironment by modulating inflammatory 395 
responses and this merits further investigation in animal models.  396 
Summary 397 
In the current study we provide the first evidence to support a mechanistic link between 398 
exposure to elevated cholesterol, biosynthesis of 27HC and EC. Analysis of human stage 1 399 
endometrial adenocarcinomas revealed expression of the key metabolising enzymes of 400 
27HC was altered in EC consistent with increased exposure to 27HC as EC progresses from 401 
well- to poorly-differentiated. Although survival rates for EC are high, incidence rates are 402 
increasing in line with rates of obesity and a rising incidence in pre- and peri-menopausal 403 
women creates unique therapeutic challenges. Based on our novel findings, we propose that 404 
exposure to 27HC may influence disease development/progression by activating ER-405 
dependent pathways to increase epithelial cell proliferation. These results suggest strategies 406 
that seek to limit exposure to 27HC through lifestyle modification, lipid-lowering drugs such 407 
as statins or novel therapeutics that target 27HC synthesis (CYP27A1 inhibitors) may be 408 
effective in reducing endometrial proliferation in women at increased risk of developing EC. 409 
Taken together our novel findings suggest that altered cholesterol metabolism, and aberrant 410 
exposure to 27HC, may contribute to the development and/or progression of endometrial 411 
cancer.  412 
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Figure legends 1 
Figure 1. 27HC signalling pathway is expressed in endometrial cancer and altered 2 
with disease severity. The expression of CYP7B1, CYP27A1, NR1H3 (LXRα) and NR1H2 3 
(LXRβ) relative to internal control gene CYC was assessed by qPCR in postmenopausal 4 
control endometrium (PM Ctrl) and in endometrial cancer tissue homogenates from well-, 5 
moderately- and poorly-differentiated endometrial adenocarcinomas. Relative expression of 6 
mRNAs encoding CYP7B1 (A) were decreased in poorly differentiated cancers compared to 7 
moderately differentiated cancers but CYP27A1 was not significantly different (B). Relative 8 
expression of mRNAs encoding NR1H3 (C; LXRα) were significantly decreased in 9 
moderately-differentiated cancers compared to post-menopausal control tissues while 10 
NR1H2 (LXRβ) was not significantly different (D). *p<0.05, **p<0.01. Kruskal-Wallis test with 11 
multiple comparisons. PM, n=9; Well n=12-30; Mod, n=42-64; Poor, n=23-32. All data are 12 
presented as mean ± SEM. 13 
Figure 2. Expression of LXR and the proliferation marker Ki67 in endometrial cancer. 14 
The expression of LXR (antibody identified both isoforms) and the proliferation marker Ki67 15 
was assessed by immunohistochemistry in endometrial cancer tissue sections. In well-16 
differentiated cancers (A), LXR was expressed throughout the tissue and localised to the 17 
nuclei of both stromal and epithelial cells (green staining). Nuclear immunoexpression of 18 
Ki67 (red staining) was detected and co-localised with LXR expression (yellow arrows) 19 
although some LXR-positive cells did not co-express Ki67 (white arrows). In moderately-20 
differentiated cancers (B) both markers were detected but did not appear to co-localise; only 21 
few cells expressed both LXR and Ki67 (yellow arrows). Most LXR-positive cells did not co-22 
express Ki67 (white arrows). This was also true of poorly differentiated cancers (C), few cells 23 
expressed both LXR and Ki67 (yellow arrows) although LXR-positive cells were found in 24 
close association with proliferating cells (white arrows). Images representative of at least 3 25 
different patients per cancer grade. Nuclear counterstain DAPI (grey). All scale bars 50µM. 26 
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Figure 3. 27HC activates LXRE- and ERE-dependent transcription in endometrial 27 
epithelial cancer cells and alters proliferation. The cholesterol metabolite 27-28 
hydoxycholesterol (27HC) is the endogenous agonist for LXR and is also classified as 29 
selective estrogen receptor modulator. The impact of 27HC on LXRE- (A-C) and ERE-30 
dependent (D-F) transcription was investigated by luciferase reporter assay in endometrial 31 
cancer cell lines; Ishikawa, RL95 and MFE280. 27HC significantly increased LXRE-32 
dependent transcription in a dose-dependent manner in each endometrial cancer cell line. 33 
27HC stimulated ERE-dependent transcription only at lower concentrations and was 34 
significantly increased by 10-8M 27HC (p<0.01) and maximally stimulated by 10-7M 27HC 35 
(p<0.0001). The 27HC effect was abrogated by co-incubation with the antiestrgoen 36 
Fulvestrant (ICI 182,780; ICI) at all concentrations of 27HC (D). 27HC did not increase ERE-37 
dependent transcription in RL95 (E) and was only increased by 10-5M 27HC (p<0.05) in 38 
MFE280 cells (F). Cell proliferation was assessed by CyQuant® direct proliferation assay in 39 
each cell line (G-I). Proliferation of Ishikawa cells was increased by 10-8M (p<0.01), 10-7M 40 
(p<0.01) and 10-6M (p<0.01) 27HC but decreased by 10-5M 27HC (p<0.0001; G). 41 
Proliferation of RL95 cells was increased by 10-7M (p<0.001), 10-6M (p<0.01) and 10-5M 42 
(p<0.001) 27HC (H). 27HC did not affect proliferation in MFE280 cells (I). *p<0.05, **p<0.01, 43 
*** p<0.001, **** p<0.0001. One sample t test and a theoretical mean of 1. All data are 44 
presented as mean ± SEM. 45 
Figure 4. LXR agonist GW3965 activates LXRE-dependent transcription and alters 46 
proliferation in endometrial epithelial cancer cells. The impact of the LXR synthetic 47 
agonist GW3965 on LXRE-dependent transcription (A-C) and on cell proliferation (D-F) was 48 
assessed in endometrial cancer cell lines; Ishikawa, RL95 and MFE280. GW3965 49 
significantly increased LXRE-dependent transcription in a dose-dependent manner in each 50 
endometrial cancer cell line. GW3965 significantly increased LXRE-dependent transcription 51 
at all concentrations assessed and was maximally increased by 10-6M GW3965 in Ishikawa 52 
cells (p<0.0001) (A) and RL95 cells (p<0.01) (B). LXRE-dependent transcription and was not 53 
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increased by 10-8M GW3965 but maximally increased by 10-5M 27HC (p<0.001) in MFE280 54 
cells (C). Cell proliferation was assessed by CyQuant® direct proliferation assay in each cell 55 
line (D-F). Proliferation of Ishikawa cells was increased by 10-8M (p<0.01) and by 10-5M 56 
27HC (p<0.01) (D). In contrast, proliferation of RL95 cells was decreased by 10-8M 57 
(p<0.001), 10-7M (p<0.001), 10-6M (p<0.01) and 10-5M (p<0.05) GW3965 (E). Proliferation of 58 
MFE280 cells was decreased by 10-8M (p<0.001), 10-7M (p<0.0001), 10-6M (p<0.0001) and 59 
10-5M (p<0.05) GW3965 (I). *p<0.05, **p<0.01, *** p<0.001, **** p<0.0001. One sample t 60 
test and a theoretical mean of 1. All data are presented as mean ± SEM. 61 
 62 
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Figure 1. 27HC signalling pathway is expressed in endometrial cancer and altered with disease severity. The 
expression of CYP7B1, CYP27A1, NR1H3 (LXRα) and NR1H2 (LXRβ) relative to internal control gene CYC was 
assessed by qPCR in postmenopausal control endometrium (PM Ctrl) and in endometrial cancer tissue 
homogenates from well-, moderately- and poorly-differentiated endometrial adenocarcinomas. Relative 
expression of mRNAs encoding CYP7B1 (A) were decreased in poorly differentiated cancers compared to 
moderately differentiated cancers but CYP27A1 was not significantly different (B). Relative expression of 
mRNAs encoding NR1H3 (C; LXRα) were significantly decreased in moderately-differentiated cancers 
compared to post-menopausal control tissues while NR1H2 (LXRβ) was not significantly different (D). 
*p<0.05, **p<0.01. Kruskal-Wallis test with multiple comparisons. PM, n=9; Well n=12-30; Mod, n=42-64; 
Poor, n=23-32. All data are presented as mean ± SEM.  
 
186x131mm (300 x 300 DPI)  
 
 
Page 24 of 28
  
 
 
Figure 2. Expression of LXR and the proliferation marker Ki67 in endometrial cancer. The expression of LXR 
(antibody identified both isoforms) and the proliferation marker Ki67 was assessed by 
immunohistochemistry in endometrial cancer tissue sections. In well-differentiated cancers (A), LXR was 
expressed throughout the tissue and localised to the nuclei of both stromal and epithelial cells (green 
staining). Nuclear immunoexpression of Ki67 (red staining) was detected and co-localised with LXR 
expression (yellow arrows) although some LXR-positive cells did not co-express Ki67 (white arrows). In 
moderately-differentiated cancers (B) both markers were detected but did not appear to co-localise; only 
few cells expressed both LXR and Ki67 (yellow arrows). Most LXR-positive cells did not co-express Ki67 
(white arrows). This was also true of poorly differentiated cancers (C), few cells expressed both LXR and 
Ki67 (yellow arrows) although LXR-positive cells were found in close association with proliferating cells 
(white arrows). Images representative of at least 3 different patients per cancer grade. Nuclear counterstain 
DAPI (grey). All scale bars 50µM.  
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Figure 3. 27HC activates LXRE- and ERE-dependent transcription in Endometrial epithelial cancer cells and 
alters proliferation. The cholesterol metabolite 27-hydoxycholesterol (27HC) is the endogenous agonist for 
LXR and is also classified as selective estrogen receptor modulator. The impact of 27HC on LXRE- (A-C) and 
ERE-dependent (D-F) transcription was investigated by luciferase reporter assay in endometrial cancer cell 
lines; Ishikawa, RL95 and MFE280. 27HC significantly increased LXRE-dependent transcription in a dose-
dependent manner in each endometrial cancer cell line. 27HC stimulated ERE-dependent transcription only 
at lower concentrations and was significantly increased by 10-8M 27HC (p<0.01) and maximally stimulated 
by 10-7M 27HC (p<0.0001). The 27HC effect was abrogated by co-incubation with the antiestrgoen 
Fulvestrant (ICI 182,780; ICI) at all concentrations of 27HC (D). 27HC did not increase ERE-dependent 
transcription in RL95 (E) and was only increased by 10-5M 27HC (p<0.05) in MFE280 cells (F). Cell 
proliferation was assessed by CyQuant® direct proliferation assay in each cell line (G-I). Proliferation of 
Ishikawa cells was increased by 10-8M (p<0.01), 10-7M (p<0.01) and 10-6M (p<0.01) 27HC but decreased 
by 10-5M 27HC (p<0.0001; G). Proliferation of RL95 cells was increased by 10-7M (p<0.001), 10-6M 
(p<0.01) and 10-5M (p<0.001) 27HC (H). 27HC did not affect proliferation in MFE280 cells (I). *p<0.05, 
**p<0.01, *** p<0.001, **** p<0.0001. One sample t test and a theoretical mean of 1. All data are 
presented as mean ± SEM.  
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Figure 4. LXR agonist GW3965 activates LXRE-dependent transcription and alters proliferation in 
Endometrial epithelial cancer cells. The impact of the LXR synthetic agonist GW3965 on LXRE-dependent 
transcription (A-C) and on cell proliferation (D-F) was assessed in endometrial cancer cell lines; Ishikawa, 
RL95 and MFE280. GW3965 significantly increased LXRE-dependent transcription in a dose-dependent 
manner in each endometrial cancer cell line. GW3965 significantly increased LXRE-dependent transcription 
at all concentrations assessed and was maximally increased by 10-6M GW3965 in Ishikawa cells (p<0.0001) 
(A) and RL95 cells (p<0.01) (B). LXRE-dependent transcription and was not increased by 10-8M GW3965 
but maximally increased by 10-5M 27HC (p<0.001) in MFE280 cells (C). Cell proliferation was assessed by 
CyQuant® direct proliferation assay in each cell line (D-F). Proliferation of Ishikawa cells was increased by 
10-8M (p<0.01) and by 10-5M 27HC (p<0.01)(D). In contrast, proliferation of RL95 cells was decreased by 
10-8M (p<0.001), 10-7M (p<0.001), 10-6M (p<0.01) and 10-5M (p<0.05) GW3965 (E). Proliferation of 
MFE280 cells was decreased by 10-8M (p<0.001), 10-7M (p<0.0001), 10-6M (p<0.0001) and 10-5M 
(p<0.05) GW3965 (I). *p<0.05, **p<0.01, *** p<0.001, **** p<0.0001. One sample t test and a 
theoretical mean of 1. All data are presented as mean ± SEM.  
 
156x93mm (300 x 300 DPI)  
 
 
Page 28 of 28
